doi:10.3969/j.issn.1004-583X.2021.01.019

Abstract

CLC Number:

R544

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.01.019

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I1/89

References 39

[1]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 慢性阻塞性肺疾病基层诊疗指南[J]. 中华全科医师杂志, 2018,17(11):856-870.
[2]	Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry[J]. Eur Respir J, 2013,41(6):1292-1301. doi: 10.1183/09031936.00079512 URL
[3]	Gao Y, Chen T, Raj JU. Endothelial and smooth muscle cell interactions in the pathobiology of pulmonary hypertension[J]. Am J Respir Cell Mol Biol, 2016,54(4):451-460. doi: 10.1165/rcmb.2015-0323TR URL
[4]	Sun DL, Li SM, Cen YY, et al. Accuracy of using serum D-dimer for diagnosis of acute intestinal ischemia: A meta-analysis[J]. Medicine (Baltimore), 2017,96(13):e6380. doi: 10.1097/MD.0000000000006380 URL
[5]	Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study[J]. Can Respir J, 2008,15(1):13-19. pmid: 18292848
[6]	王静, 万钧, 王辰, 等. 慢性肺部疾病所致肺动脉高压靶向药物治疗研究进展[J]. 中国实用内科杂志, 2019,39(2):174-178.
[7]	Mekov E, Slavova Y, Tsakova A, et al. Metabolic syndrome in hospitalized patients with chronic obstructive pulmonary disease[J]. Peer J, 2015,3:e1068. doi: 10.7717/peerj.1068 URL
[8]	杨生岳, 戴胜归. 高原地区慢性肺心病诊断与治疗中值得注意的几个特殊问题[J]. 中华肺部疾病杂志(电子版), 2014,7(3):243-246.
[9]	Hernandez P, Balter MS, Bourbeau J, et al. Canadian practice assessment in chronic obstructive pulmonary disease: respiratory specialist physician perception versus patient reality[J]. Can Respir J, 2013,20(2):97-105. doi: 10.1155/2013/369019 URL
[10]	Cracowski JL, Chabot F, Labarère J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension[J]. Eur Respir J, 2014,43(3):915-917. doi: 10.1183/09031936.00151313 URL
[11]	Kim HJ, Yoo HY. Hypoxic pulmonary vasoconstriction and vascular contractility in monocrotaline-induced pulmonary arterial hypertensive rats[J]. Korean J Physiol Pharmacol, 2016,20(6):641-647. doi: 10.4196/kjpp.2016.20.6.641 URL
[12]	舒微, 梁民勇, 向明钧. 慢性阻塞性肺疾病并发肺动脉高压的研究进展[J]. 中国当代医药. 2019,26(25):32-35.
[13]	Shimoda LA, Yun X, Sikka G. Revisiting the role of hypoxia-inducible factors in pulmonary hypertension[J]. Curr Opin Physiol, 2019,7:33-40.
[14]	Xiong PY, Potus F, Chan W, et al. Models and molecular mechanisms of world health organization group 2 to 4 pulmonary hypertension[J]. Hypertension, 2018,71(1):34-55. doi: 10.1161/HYPERTENSIONAHA.117.08824 pmid: 29158355
[15]	Kojima H, Tokunou T, Takahara Y, et al. Hypoxia-inducible factor-1 α deletion in myeloid lineage attenuates hypoxia-induced pulmonary hypertension[J]. Physiol Rep, 2019,7(7):e14025. doi: 10.14814/phy2.14025 URL
[16]	Ricard N, Tu L, Le Hiress M, et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension[J]. Circulation, 2014,129(15):1586-1597. doi: 10.1161/CIRCULATIONAHA.113.007469 URL
[17]	Itoh A, Nishihira J, Makita H, et al. Effects of IL-1beta, TNF-alpha, and macrophage migration inhibitory factor on prostacyclin synjournal in rat pulmonary artery smooth muscle cells[J]. Respirology, 2003,8(4):467-472. doi: 10.1046/j.1440-1843.2003.00491.x URL
[18]	Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension[J]. J Mol Med (Berl), 2011,89(8):771-783. doi: 10.1007/s00109-011-0762-2 URL
[19]	Chen YW, Leung JM, Sin DD. A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation[J]. PLoS One, 2016,11(7):e0158843. doi: 10.1371/journal.pone.0158843 URL
[20]	黄茉莉, 梅晓冬, 王卫阳. 慢性阻塞性肺疾病患者血清炎症因子水平及其临床意义[J]. 中国老年学杂志, 2019,39(24):5973-5976.
[21]	Chauhan AK, Kisucka J, Lamb CB, et al. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins[J]. Blood, 2007,109(6):2424-2429. pmid: 17119108
[22]	Oszajca K, Wroński K, Janiszewska G, et al. The study of t-PA, u-PA and PAI-1 genes polymorphisms in patients with abdominal aortic aneurysm[J]. Mol Biol Rep, 2014,41(5):2859-2864. doi: 10.1007/s11033-014-3141-6 URL
[23]	何新文. 浅论肺癌与肺癌合并肺部感染患者血常规指标、血清炎性因子及凝血指标的差异性[J]. 当代医药论丛, 2017,5(10):8-9.
[24]	刘领, 吴文杰, 杨霁, 等. 慢性阻塞性肺疾病患者炎症反应与凝血功能异常的关系[J]. 中国医刊, 2015,50(8):47-50.
[25]	李志伟, 王著军, 徐旭, 等. TNF-α、LPS、IL-6、PAT与颅脑损伤后急性凝血功能障碍的相关性[J]. 中国临床神经外科杂志, 2015,20(1):25-27.
[26]	Aziz M, Jacob A, Wang P. Revisiting caspases in sepsis[J]. Cell Death Dis, 2014,5(11):e1526. doi: 10.1038/cddis.2014.488 URL
[27]	Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation[J]. J Intensive Care, 2016,4:23. doi: 10.1186/s40560-016-0149-0 pmid: 27011792
[28]	戴艳枝, 王晓华, 刘秋玲, 等. 白细胞介素-1β、白细胞介素-8及肿瘤坏死因子-α与房颤伴凝血功能异常的相关性[J]. 中国当代医药, 2019,26(23):4-7.
[29]	李少昆, 安生花, 郭凤龙, 等. 肺癌患者血清TNF-α、IL-6与凝血功能的相关性研究[J]. 实用癌症杂志. 2018,33(11):1773-1776.
[30]	Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis[J]. Arterioscler Thromb Vasc Biol, 2007,27(8):1687-1693. doi: 10.1161/ATVBAHA.107.141911 URL
[31]	Konoeda H, Yamaki T, Hamahata A, et al. Incidence of deep vein thrombosis in patients undergoing breast reconstruction with autologous tissue transfer[J]. Phlebology, 2017,32(4):282-288. doi: 10.1177/0268355516680427 pmid: 27864561
[32]	Cote DJ, Smith TR. Venous thromboembolism in brain tumor patients[J]. J Clin Neurosci, 2016,25:13-18. doi: 10.1016/j.jocn.2015.05.053 URL
[33]	Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation[J]. Trends Cardiovasc Med, 2016,26(4):297-303. doi: 10.1016/j.tcm.2015.12.001 URL
[34]	Rehani T, Mathson K, Belcher JD, et al. Heme potently stimulates tissue factor expression by peripheral blood monocytes: a novel mechanism for thrombosis in intravascular hemolytic diseases[J]. Blood, 2013,122(21):2215. doi: 10.1182/blood.V122.21.2215.2215 URL
[35]	Mitroulis I, Kambas K, Anyfanti P, et aI. The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention[J]. Expert Opin Ther Targets, 2011,15(1):75-89. doi: 10.1517/14728222.2011.532788 URL
[36]	Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood[J]. Blood, 2005,105(7):2764-2770. doi: 10.1182/blood-2004-09-3567 URL
[37]	Maugeri N, Manfredi AA. Tissue factor expressed by neutrophils: another piece in the vascular inflammation puzzle[J]. Semin Thromb Hemost, 2015,41(7):728-736. doi: 10.1055/s-00000077 URL
[38]	赵晟, 姚小燕, 薛新颖, 等. 低压低氧性肺动脉高压中组织因子致高凝状态的研究[J]. 中国分子心脏病学杂志, 2016,16(6):1920-1922.
[39]	Andreasen EB, Nielsen OL, Tranholm M, et al. Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation[J]. Vet Comp Oncol, 2016,14(2):191-201. doi: 10.1111/vco.12089 pmid: 24674618

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 39

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Yi, Cui Kun, Liu Chang, Zhao Haotian, Li Li, Xue Hongyuan. Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension [J]. Clinical Focus, 2023, 38(12): 1073-1077.
[2]	Jiang Ji, Zhu Xiaogang, Jiang Shan, Dawa Zhaba, Cen Qiang. Risk factors of proteinuria in hypertensive people living at high altitude for generations [J]. Clinical Focus, 2023, 38(12): 1086-1090.
[3]	Xu Yang, Xue Ling. Influencing factors for mild cognitive impairment in type H hypertension patients combined with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(10): 887-892.
[4]	. [J]. Clinical Focus, 2023, 38(2): 181-184.
[5]	. [J]. Clinical Focus, 2023, 38(1): 88-92.
[6]	Yin Yikun, Yin Xunwei, Wang Jialin, Sun Junzhi. Impacts of Tai Chi exercise cycle on blood pressure and cardiovascular risk factors in essential hypertension: a systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(7): 599-606.
[7]	An Qinyan, Jiang Rong, Kang Bin, Du Ming, Zhou Renming, Zhao Hongjuan, Duan Yi, Lu Fei, Liu Jinming. Levels and clinical significance of RDW, NT-proBNP, BigET-1, HMGB1 in patients with idiopathic pulmonary arterial hypertension [J]. Clinical Focus, 2021, 36(11): 1001-1004.
[8]	. [J]. Clinical Focus, 2021, 36(8): 744-748.
[9]	Gong Tao, Hu Yueyuan, Gao Yun, Guo Chang, Shen Huinan, Wang Dongyu. Relationship between H-type hypertension and severity of neurological deficit in early acute cerebral infarction of LAA [J]. Clinical Focus, 2021, 36(7): 612-615.
[10]	. [J]. Clinical Focus, 2021, 36(6): 566-568.
[11]	. [J]. Clinical Focus, 2021, 36(3): 270-276.
[12]	Liu Xiaoteng, Shan Weichao, Hou Ruitian, Lin Jinping, Gao Yu, Jin Fengbiao, Liu Chang. Correlation between serum hypersensitive C-reactive protein, lipoprotein-related phospholipase A₂and senile essential hypertension complicated with type 2 diabetes [J]. Clinical Focus, 2021, 36(1): 25-29.
[13]	Liang Yuling, Li Wenxi, Gu Xuewen. Randomized controlled trial of Tianma Gouteng Decoction and irbesartan in treatment of essential hypertension [J]. Clinical Focus, 2020, 35(12): 1097-1100.
[14]	Zhu Bin;Wang Yongxia. Correlation between carotid plaque and blood pressure variation in patients with hypertension [J]. Clinical Focus, 2015, 30(12): 1360-1362.
[15]	Quan Feng;Fan Xuemei;Fang Wenlong. Clinical study of systemic lupus erythematosus associated pulmonary hypertension [J]. Clinical Focus, 2015, 30(12): 1402-1.40414e+007.